To induce immunotolerance, chicken embryos were inoculated with BSA on embryonic incubation day (EID) 20. All hatched chickens were challenged with BSA four times at 10-day intervals, beginning at 3 weeks of age. Serum anti-BSA antibodies were analyzed and our results show that immunotolerance was obtained in the group micro-injected with 1 mg of BSA. We administered BSA labeled with 2,4-dinitrophenyl (DNP) into blood vessels on EID 20 and detected the distribution of BSA by immunohistochemistry. Our results show that DNP-BSA was located in the bursal cortex, thymus and spleen. PBMCs were separated on the seventh day after the fourth immunization to determine the effect of treatments on lymphocytes and the percentage of CD4 1 T cells among the CD3 1 T cell population. Results from these experiments show that there was an influence on T lymphocyte proliferation, with the number of CD4 1 T cells in the tolerance group significantly increased. To determine whether tolerance was induced in B cells, 2,4,6-trinitrophenyl coupled to BSA (TNP-BSA) was inoculated into birds, followed by detection of anti-TNP antibodies in the serum. Immunological tolerance in B cells was not observed following these experiments. The results from our study demonstrate that immunological tolerance was induced in T cells when 1 mg of BSA was microinjected on EID 20.
Introduction
The clonal selection theory as proposed by Burnet (1) states that when lymphoid cells encounter antigens during their immature phase of development, somehow they can specifically suppress future responses of the immune system to that antigen when the animal reaches maturity. This theory was subsequently verified by Billingham et al. (2) . It is well known that immunological tolerance or unresponsiveness can be artificially induced in animals (3, 4) . Wolfe et al. (5) induced tolerance in chickens by injecting large doses of BSA into newly hatched chickens. Similar results were observed by Stevens et al. (6) , who injected human serum albumin (HSA) into chicken embryo yolk sacs. Surgical bursectomy is another method that can substantially increase the suppression of antibody formation and prolong the duration of the tolerance induced by either BSA (7) or HSA (8) . Like mammals, oral tolerance in chickens may be induced following the oral administration of antigens (9) (10) (11) . Avian species have a different ontogenesis compared with mammals, as avian embryos develop outside the mother, providing advantageous conditions for inoculating antigens during embryogenesis. To the best of our knowledge, embryonic blood vessel antigen inoculation in chickens for induction of immunological tolerance has rarely been explored. In our laboratory, previous experimental data has shown that the introduction of an exogenous protein into early chicken embryonic blood leads to immunotolerance of that protein in the hatched chicken (12) . Some early embryonic blood cells possibly store antigen for the establishment of self-tolerance before B-and T-cell maturation (13) . In this study, we examined whether immunological tolerance in chickens inoculated with xenogeneic antigens could be induced at a later stage of embryonic development.
Until recently, mechanisms of immunological tolerance included T-and B-cell selection. Negative selection of T cells mainly occurred when immature T cells encountered antigens in the thymus, but there was no response by the T cells when they encountered the same antigen. The self-antigen was expressed in the thymus (14, 15) , delivered across blood into the circulatory system (16, 17) , or obtained by dendritic cells at the periphery and presented to the thymus (18) . Although it is different from T cells, the self-antigen is also important for B-cell selection. The fact that the receptor on B cells recognizes antigens is critical for inducing negative selection or a lack of responses by clones. Nemazee and Burki (19) first proved that negative selection occurred with B cells in the bone marrow by showing that when immunoglobulins on B cells were continuously taken up over a prolonged period, B-cell apoptosis would be the result. Another mechanism of immunological tolerance was that regulated T cells emerged during T-cell development and acted upon specific antigens.
Genetically engineered cells transplanted into animals could be an economic way of producing specific proteins for the pharmaceutical industry. The target protein produced should usually be a xenogeneic antigen for receptor animals. Strong immune responses may be triggered, protein production suppressed and even the cells with surface expression of the antigen rejected. Mohammed et al. (20) intravenously injected a bursal lymphoma cell line (DT40) that expressed and secreted recombinant human immunoglobulins (rhIgs) into Hyline SCE hens for deposition into eggs. They found that rhIgs were first detected in the egg yolk 6 days after injection; and the content of rhIgs was highest in eggs laid 12 days after injection of the cell but declined soon after as a result of immune responses to circulating rhIgs in the chicken. It is conceivable that more rhIgs could be produced by hens if the formation of anti-human Ig antibodies was suppressed (21) . The existence of an immune system in animals makes it difficult for the application of transgenic technology. To overcome this problem, immune tolerance studies have become very important.
The purpose of this study was to induce immunological tolerance to xenogeneic antigens by introducing antigens into late-stage chicken embryos and research the mechanisms of tolerance.
Methods

Fertilized eggs and chickens
Fertilized eggs from Jingbai 938, a white leghorn (Gallus domesticus) strain purchased from the Experimental Station of the China Agricultural University, were incubated at 37.6°C in a forced air incubator at 53-63% relative humidity with 90°tilting once every hour (P-008B Biotype, Showa Furanki, Saitama, Japan).
Preparation of proteins
BSA, ovalbumin (OVA), HSA, dinitrophenyl-BSA (DNP-BSA) and trinitrophenyl (TNP) were purchased from Sigma-Aldrich (St Louis, MO, USA). TNP-BSA, TNP-OVA and TNP-HSA were prepared according to previously described methods (22) , with modifications as described by Wu et al. (13) . Briefly, 50 mg of OVA (or 80 mg of BSA or HSA) was dissolved in 2.5 ml of 0.1 M NaHCO 3 buffer (pH 9.5) and slowly added to 222 ll of sterile deionized water containing 95 ll of 5% TNP, while stirring. The mixture was covered with aluminum foil and incubated overnight at 4°C with gentle stirring, then dialyzed five times against 2 l of saline and the absorbance measured in a spectrophotometer at 280 and 340 nm. The TNP:protein ratio was then calculated, with the ratios of 6.75 for OVA, 3.54 for BSA and 4.69 for HSA.
Tolerance induction by embryonic blood vessel microinjection
A small window was opened in the air chamber and antigens (400 lg or 1 mg of BSA or 1 mg of TNP-BSA) were directly injected into embryonic blood vessels on embryonic incubation day (EID) 20. The window was sealed and the eggs incubated with the blunt end facing upwards until hatching.
Post-hatch immunization
In the BSA experiment, all chickens were challenged four times with BSA (200 lg of BSA per chicken each dose). The initial immunization was administered by dorsal hypodermic injection with antigens emulsified with an equal volume of Freund's Complete Adjuvant (Sigma, St Louis, MO, USA). This was followed by two injections with antigens emulsified in Freund's Incomplete Adjuvant (Sigma) at 10-day intervals. Finally, the chickens were challenged with 200 lg of antigens by intramuscular injection in the absence of adjuvant after another 10-day interval according to previous methods (9) .
In the TNP-BSA experiment, the chickens (3-week-old) were challenged with 100 lg TNP-HSA and 100 lg HSA with an equal volume of Freund's Complete Adjuvant per chicken once. Because TNP has a hapten epitope, it can be identified by a single specific B-cell clone to induce B-cell tolerance. To avoid BSA-specific T cells being injured, we immunized chickens with TNP-HSA 3 weeks later, changing the hapten carrier from BSA to HSA. HSA was used as a reference for the immune response. The levels of anti-TNP and anti-HSA antibodies were determined by ELISA.
Enzyme-linked immunosorbent assay
The levels of specific anti-BSA, -TNP and -HSA antibodies in the sera were determined by ELISA according to previous methods (13) . Peripheral blood was obtained by venipuncture and serum was separated by coagulation at 37°C for 1 h followed by centrifugation (10000 3 g, 10 min, 4°C). ELISA plates (96-wells; Sigma-Aldrich) were coated with 2 lg ml À1 BSA, TNP-OVA or HSA dissolved in a carbonatebicarbonate buffer (pH 9.6) and incubated at 4°C overnight. The plates were then washed with phosphate buffer (pH 7.4) containing 0.05% Tween-20 (PBST), and the remaining binding sites blocked with 1% gelatin dissolved in carbonate-bicarbonate buffer (pH 9.6) for 1 h at 37°C. The plates were washed again with PBST. Serum was diluted in 0.1% gelatin/PBST (pH 7.4) and incubated at 37°C for 1.5 h. Plates were washed once again and incubated with goat antichicken IgG and IgM peroxidase-conjugated antibodies (Southern Biotechnology Associates, Birmingham, AL, USA) at 37°C for 1 h before color development with 3,3#,5,5#-tetramethylbenzidine. The levels of anti-TNP or anti-HSA antibodies in the sera were calculated from the absorbance at 450 nm as determined by a microplate reader (Model 550; Bio-Rad, Hercules, CA, USA).
Immunohistochemistry
Chickens were micro-injected with 1 mg of DNP-BSA via the allantoic membrane vein on EID 20. The distribution of DNP-BSA in immune tissues was detected at 6 h post-injection using a polyclonal rabbit anti-DNP antibody (Sigma-Aldrich) followed by a horseradish peroxidase-conjugated goat anti-rabbit IgG. The positive loci were revealed using an ABC kit (Vector Labs, Burlingame, CA, USA) followed by counter staining with hematoxylin. In the same tissue, negative controls were used to avoid non-specific development and treated as described above except that PBS was used instead of anti-DNP antibody.
Lymphocyte proliferation
Uncoagulated peripheral blood samples were obtained via venipuncture and lymphocytes prepared according to a previously described method (23) . An amount of chicken lymphocyte separation medium (TBD, Tianjin, China) equal to the original volume of the blood sample was added to a blood collection tube, followed by centrifugation (425 3 g, 20 min). PBMCs were harvested from the interface, immediately washed twice in D-Hanks solution and centrifuged at 425 3 g for 10 min at room temperature. After washing again, the cells were resuspended in 2 ml of complete RPMI 1640 medium (HyClone, Thermo Scientific, Waltham, MA, USA) supplemented with 10% chicken serum (HyClone), 100 U ml À1 penicillin and 100 lg ml À1 streptomycin. Viable cells were counted using trypan blue exclusion, diluted to 1 3 10 7 cells ml À1 and cultured at a density of 50 ll per well in 96-well microliter plates. Triplicate lymphocyte cultures (5 3 10 5 cells per well) were stimulated in complete RPMI 1640 medium with or without BSA (500 lg ml 
Flow cytometry
Peripheral blood mixed with heparin sodium was obtained via venipuncture and PBMCs were separated in lymphocyte separation medium (TBD, Tianjin, China). The Fc receptors were blocked with an anti-mouse CD16/CD32 antibody (eBioscience, San Diego, CA, USA) for 30 min at 4°C. PBMCs were stained with or without spectral red-conjugated mouse anti-chicken CD3 (CT3) and FITC-conjugated anti-chicken CD4 (CT4) (Southern Biotechnology Associates). A FACScalibur (Becton Dickinson, Franklin, NJ, USA) was used to conduct flow cytometry and analyze data.
All animal care and handling procedures were performed in accordance with the standards of China Agricultural University.
Statistical analysis
Differences in all experiments were analyzed using SPSS software (v13.0; SPSS Inc., Chicago, IL, USA) and an independent sample t-test. A P-value <0.05 was considered statistically significant.
Results
Induction of immunological tolerance to BSA BSA injection (400 lg treatment). Eighteen fertilized white leghorn eggs were inoculated with 400 lg of BSA via embryonic blood vessel micro-injection at EID 20. Nine chickens were hatched from the treated eggs (50% hatchability) but three chicks died soon after hatching. Three weeks later, six chickens treated with BSA (experimental group) and six without BSA (positive control group) were immunized with 200 lg of BSA and Freund's Complete or Incomplete Adjuvant (v:v = 1:1) three times at 10-day intervals beginning at 3 weeks of age. The negative controls for use in the ELISAs were the sera derived from the unimmunized chickens. Our results show that 10 days after the first immunization, the levels of anti-BSA IgY in the experimental group were not significantly lower than those in the positive control group (0.231 6 0.173, n = 6 versus 0.520 6 0.373, n = 6; P = 0.128). Ten days after the second immunization, the anti-BSA IgY levels in the experimental group were significantly lower than those in the positive control group (0.621 6 0.466, n = 6 versus 1.254 6 0.478, n = 6; P = 0.037). However, 10 days after the third immunization, the anti-BSA IgY levels in the experimental group were not significantly lower than those in the positive control group (1.042 6 0.519, n = 6 versus 1.569 6 0.491, n = 6; P = 0.101).
BSA injection (1 mg treatment). Thirty-six fertilized white leghorn eggs were inoculated with 1 mg of BSA via embryonic blood vessel micro-injection at EID 20. Twenty chickens were hatched from the treated eggs (56% hatchability) but eight chicks died soon after hatching. Three weeks later, 12 chickens treated with BSA (experimental group) and 7 without BSA (positive controls) were immunized with 200 lg of BSA plus Freund's Complete or Incomplete Adjuvant (v:v = 1:1) four times at 10-day intervals beginning at 3 weeks of age. Ten days after the first immunization, the anti-BSA IgY levels in the experimental group were significantly lower than those in the positive control group (0.180 6 0.100, n = 12 versus 0.992 6 0.388, n = 7; P = 0.001). There was no significant difference between the experimental group and the negative samples when multiplied by 2.1 (the threshold of the standard that served as a negative judgment; 0.180 6 0.100, n = 12 versus 0.163 6 0.319, n = 8; P = 0.660). Ten days after the second immunization, the anti-BSA IgY levels in the experimental group were significantly lower than those in the positive control group (0.103 6 0.077, n = 7 versus 1.015 6 0.473, n = 12; P = 0.001) and there was no significant difference between the experimental group and negative samples multiplied by 2.1 (0.103 6 0.077, n = 12 versus 0.108 6 0.009, n = 8; P = 0.832). Ten days after the third immunization, the anti-BSA IgY levels in the experimental group were significantly lower than those in the positive
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control group (0.127 6 0.108, n = 12 versus 1.473 6 0.345, n = 6; P = 0.000) and there was no significant difference between the experimental group and negative samples multiplied by 2.1 (0.127 6 0.108, n = 12 versus 0.108 6 0.009, n = 8; P = 0.549). Seven days after the fourth immunization, the anti-BSA IgY levels in the experimental group were significantly lower than those in the positive control group (0.149 6 0.172, n = 10 versus 1.551 6 0.459, n = 7; P = 0.001) with no significant difference between the experimental group and negative samples multiplied by 2.1 (0.149 6 0.172, n = 10 versus 0.088 6 0.05, n = 8; P = 0.367) (Fig. 1a) . Eight days after the first immunization, the levels of anti-BSA IgM in the experimental group were significantly lower than those in the positive control group (0.164 6 0.066, n = 12 versus 0.649 6 0.232, n = 7; P = 0.001) and there was no significant difference between the experimental group and negative samples (0.180 6 0.100, n = 12 versus 0.120 6 0.014, n = 8; P = 0.046; Fig. 1b) . These results show that injection of only 1 mg of BSA can induce tolerance.
TNP-BSA injection (1 mg treatment). Fourteen chickens injected with 1 mg BSA on the 20 EID were used as the experimental group and five untreated chickens were used as the positive controls. All chickens (3-weeks-old) were challenged with 100 lg of TNP-HSA and 100 lg of HSA. Ten days after the first immunization, the anti-TNP IgY levels in the experimental group were significantly higher than those in the positive control group (1.562 6 0.088, n = 14 versus 0.779 6 0.190, n = 5; P = 0.001). The anti-HSA IgY levels were not significantly different between the experimental group and negative controls (0.867 6 0.094, n = 14 versus 0.960 6 0.114, n = 5; P = 0.825; Fig. 2) .
Immunohistochemistry
After the 6 h micro-injection of DNP-BSA via blood vessels on EID 20, proteins were found to be mainly distributed in the bursal cortex, thymus and spleen (Fig. 3) . This indicated that proteins in the blood can be delivered to specific positions in immune tissues.
Lymphocyte proliferation
Six experimental chickens were selected based on the ELISA results and five positive controls were used for lymphocyte proliferation. The PBMCs were separated on the seventh day after the fourth immunization to examine the function of the lymphocytes. Our results shown that the SI was significantly lower in the experimental group compared with the positive controls (1.099 6 0.113, n = 6 versus 1.624 6 0.422, n = 5; P = 0.048) after ConA stimulation. There were no significant differences after LPS (1.230 6 0.137, n = 6 versus 1.219 6 0.091, n = 5; P = 0.874) and BSA stimulation (1.032 6 0.157, n = 6 versus 0.919 6 0.119, n = 5; P = 0.22; Fig. 4 ).
Flow cytometry
PBMCs were separated by flow cytometry on the seventh day after the fourth immunization to determine the proportion of CD4 + T cells among CD3 + T cells. Our results show that the ratio of CD4 + to CD3 + cells in the experimental group were significantly higher than those in the positive control group (0.623 6 0.052, n = 9 versus 0.535 6 0.057, n = 7; P = 0.006) and significantly higher than those in the negative control group (0.623 6 0.052, n = 9 versus 0.538 6 0.086, n = 6; P = 0.032; Fig. 5 ). 
Discussion
We micro-injected different doses of BSA into blood vessels on EID 20, followed by immunization and determined the concentration and amount of anti-BSA antibodies by ELISA. The injection of 400 lg of BSA induced tolerance after 10 days following the second immunization, but this was soon ablated by the next immunization. The injection of 1 mg of BSA induced effective tolerance, which indicated that the dose of BSA is important for the induction of immunological tolerance. To research the mechanisms of tolerance, we carried out a number of experiments. First, to detect the distribution of BSA in the immune system after injection on EID 20, we labeled BSA with DNP. The results show that protein was delivered via blood circulation and was located in the bursal cortex, spleen and thymus but not in the bursal medulla; indicating that protein entered into the immune system to induce tolerance.
Second, we separated the PBMCs from the chickens injected with 1 mg of BSA on EID 20, 7 days after the fourth immunization to detect the ratio of CD4 + /CD3 + T cells and lymphocyte proliferation stimulated by ConA, LPS and BSA. The results show that the ratio of CD4 + /CD3 + T cells was significantly higher and lymphocyte proliferation stimulated by ConA significantly lower in the experimental group than those in the positive control groups. There was no significant difference for lymphocyte proliferation stimulated by LPS and BSA, indicating that immunological tolerance was induced in T cells but not B cells. Moreover, BSA-specific T cells were not influenced after lymphocyte proliferation. One possible explanation for this is that BSA might simulate CD4 + regulatory T cells to proliferate, thereby inhibiting BSA-specific CD4 + T cell (except regulatory T cell) proliferation and influence anti-BSA antibodies forming. Another explanation might be that BSA-specific T cells, including CD4
+ regulatory T cells and CD4
+ T cells (except regulatory T cells), and the results in the BSA lymphocyte proliferation were the SI of all the BSA-specific CD4 + T cells. In the experimental group, the 
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number of CD4 + T cells (except regulatory T cells) decreased and CD4
+ regulatory T cells increased. The opposite effect was evident in the positive control group; therefore, the result of BSA-specific lymphocyte proliferation was not significantly different between two groups. Regulatory T cells seemed to play a major role in the tolerance induced, as described by Sakaguchi (24) , who suggested that CD4 + regulatory T cells naturally arose for immunologic self-tolerance and the negative control of immune responses.
Third, to further clarify whether tolerance was induced by B cells, we injected TNP-BSA into chickens on EID 20. All chickens were immunized with TNP-HSA and HSA. The results show that the group injected with TNP-BSA were significantly higher than in the positive control groups, indicating that it was difficult for B cells to induce tolerance on EID 20. In contrast, it appeared that the immune response to TNP increased in adult chickens.
To the best of our knowledge, embryonic blood vessel antigen inoculation in chickens to induce immunologic tolerance has not been explored in previous studies. Using this type of inoculation, antigens can be introduced at late developmental stages to explore the efficacy of heightened immunotolerance induction.
In conclusion, immunologic tolerance can be induced in chickens inoculated with 1 mg of BSA on EID 20. A lower dose of antigen for micro-injection could not induce tolerance. In ovo inoculation may be more suitable for producing tolerant chickens on a larger scale because of easier manipulation and higher hatching rates. The establishment of tolerance in chickens using later embryonic inoculation of the target antigen may be used in transgenic applications and prevent autoimmune diseases. 
